In addition, the FDA approved NextAR’s shoulder application, and cleared the system’s knee application last year.
NextAR is designed to improve surgical accuracy and reduce the cost per case by eliminating robotic arms or other OR equipment operators that require a lot of space in the operating room, according to the company.
The system includes artificial intelligence and machine learning tools to improve preoperative planning.
“We wanted to take another step forward in personalized medicine, improving accuracy in computer-assisted surgery,” Medacta CEO Francesco Siccardi said in a May 27 news release. “We are proud to have developed an extremely versatile platform, with a single, compact hardware that applies to both joint and spine applications.”
Medacta said the technology is ideal for ASCs as it requires less OR space, has a low upfront capital investment and lower cost per case compared to other surgical technologies.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
